stockrow
Friday 6 November 2026
Export ETON’s income statement to Excel — free account
Eton Pharmaceuticals, Inc.
ETON Healthcare Drug Manufacturers Specialty & Generic
Eton Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $80.0 million, up 104.9% from fiscal 2024.
- Revenue
- +157.9%
- EPS
- +1,857.1%
- Free cash flow
- +172.6%
- Total debt
- −24.0%
Quarter to September 2026, against a year earlier
54.21
7.06
+14.97%
Follow ETON
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 77.02 | 29.09 |
P/S ratio |
5.69 | 7.75 | 9.48 | 10.46 | |
P/FCF ratio |
220.99 | 0.00 | 0.00 | 73.81 | |
P/Operating CF |
(39.39) | 90.94 | 137.92 | 41.88 | |
P/B ratio |
17.40 | 22.00 | 21.48 | 16.98 | |
Price to Tangible BV |
0.00 | 0.00 | 1,103.24 | 34.61 | |
EV/Sales |
5.75 | 7.87 | 9.49 | 10.23 | |
EV/EBITDA |
117.97 | 101.83 | 46.63 | 31.15 | |
EV/Operating CF |
43.67 | 43.21 | 66.18 | 37.63 | |
EV/FCF |
223.23 | (88.88) | (119.42) | 72.18 | |
Quick Ratio |
0.98 | 0.75 | 1.15 | 1.52 | |
Current Ratio |
1.57 | 1.21 | 1.52 | 1.79 | |
Net Debt/EBITDA |
1.26 | 3.03 | 0.07 | (1.32) | |
Debt/Assets |
33.17% | 31.47% | 24.09% | 14.67% | |
Debt/Equity |
1.17 | 1.00 | 0.60 | 0.27 | |
Asset Turnover |
0.95 | 0.96 | 0.97 | 1.08 | |
Operating CF/Net income |
(7.79) | 4.77 | 0.63 | 1.00 | |
Capex/Depreciation |
(0.04) | (12.07) | 0.00 | (1.96) | |
Interest Coverage |
— | 2.87 | 11.89 | 35.08 | |
Research and Development Expense of Revenue |
8.36% | 7.73% | 2.64% | 9.10% | |
Selling, General and Administrative Expense of Revenue |
41.61% | 43.05% | 30.93% | 27.65% | |
Intangible Assets out of Total Assets |
0.34 | 0.45 | 0.39 | 0.28 | |
Share Based Compensation of Revenue |
5.28% | 6.26% | 3.91% | 5.71% | |
Graham Net Nets |
(0.01) | (0.02) | 0.00 | 0.02 | |
Graham Number |
0.00 | 0.00 | 4.22 | 10.99 | |
Earnings Yield |
(1.01%) | (0.20%) | 1.30% | 3.44% | |
Free Cash Flow Yield |
0.45% | (1.14%) | (0.84%) | 1.35% | |
Revenue per Share |
0.79 | 0.89 | 1.36 | 2.02 | |
Operating CF per Share |
(0.43) | 0.27 | 0.26 | 1.23 | |
Capex per Share |
0.00 | (0.55) | 0.00 | (0.11) | |
Free Cash Flow per Share |
(0.43) | (0.28) | 0.26 | 1.12 | |
Cash per Share |
0.96 | 0.72 | 0.97 | 1.94 | |
Shareholders Equity per Share |
0.97 | 1.12 | 1.69 | 3.03 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.97 | 1.12 | 1.69 | 3.03 | |
Free Cash Flow |
(11.60) | (7.67) | 7.26 | 32.00 | |
Working Capital |
22.09 | 9.07 | 23.48 | 42.69 | |
Capital Expenditures |
(0.05) | (15.07) | 0.01 | (3.24) | |
Net Current Asset Value |
(5.38) | (13.85) | (0.62) | 26.43 | |
EV/EBIT |
0.00 | 335.53 | 61.42 | 35.47 | |
Capex to Sales |
0.00 | 0.62 | 0.00 | 0.06 | |
Price to Operating Income |
0.00 | 330.10 | 61.36 | 36.27 | |
| Other line items | |||||
Average Receivables |
8.56 | 14.90 | 19.67 | 19.75 | |
Average Payables |
7.57 | 9.18 | 13.27 | 15.38 | |
Average Inventory |
15.33 | 14.04 | 16.97 | 13.97 | |
Average Assets |
84.12 | 90.87 | 108.74 | 130.89 | |
Average Common Equity |
25.29 | 27.53 | 35.27 | 55.02 |
Columns are period end dates · fundamentals updated 5 Nov 2026